Abstract��OBJECTIVE To provide the basis for biapenem against Acinetobacter baumannii infection in ICU patients in our hospital. METHODS One hundred-five strains of ABA were collected. The MICs of biapenem against bacteria were measured by double broth dilution method. Four therapeutics regimens (0.3 g, q12 h; 0.3 g, q8 h; 0.3 g, q6 h; 0.6 g, q12 h) in traditional short-time infusion, extended infusion(3, 4h) and two-step infusion(1.5-5.5 h) were simulated by using the Monte Carlo simulation, then the PTAs and CRFs were calculated. RESULTS CFRs of all treatments of biapenem against ABA infection in ICU subjects were ��90%; but for non MDR-ABA, all biapenem regimens�� CFR were ��90% except biapenem 0.3g, q12 h(0.5 h) and 0.3 g, q12 h (two-step infusion for 1.5h). PTAs of the whole regimens were ��90% when MIC��2 mg��L-1. Extended infusion and two-step infusion got the similar PTAs and CFRs with a similar time when the regimens obtained target, more than short infusion obviously. CONCLUSION Biapenem alone should avoid for ABA infection as expiry therapy in ICU population in our hospital. Extended infusion and two-step infusion should be priority selection as target therapy according to sensitivity test.
�콨��,������,�˼̺�,Ѧ��,�߽�,л��,���շ�,������. ���ؿ���ģ������ICU���������˾���Ⱦ�бȰ����ϵĸ�ҩ����[J]. �й�ҩѧ��־, 2017, 52(24): 2218-2222.
ZHU Jian-guo, HANG Yong-fu, GU Ji-hong, XUE Ling, GAO Jie, XIE Cheng, ZHANG Xian-feng, MIAO Li-yan. Evaluation of Therapeutic Regimens of Biapenem Against Acinetobacter Baumannii Infection in ICU Subjects by Monte Carlo Simulation. Chinese Pharmaceutical Journal, 2017, 52(24): 2218-2222.
CHEN B Y, HE L X, HU B J, et al. Chinese Expert Consensus for the Diagnosis, Treatment, Prevention and Control of Acinetobacter Baumannii Infection[J]. Natl Med J China(�л�ҽѧ��־), 2012, 92(2):76-85.
[2]
HU F P, ZHU D M, WANG F, et al. CHINET 2014 surveillance of bacterial resistance in China[J]. Chin J Infect Chemother(�й���Ⱦ�뻯����־), 2015, 15(5):401-410.
[3]
PAPICH M G. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs[J]. Vet Microbiol, 2014,171(3-4):480-486.
[4]
WAELE D E,LIPMAN J, AKOVA M, et al. Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients[J]. Intensive Care Med, 2014,40(9):1340-1351.
[5]
MACVANE S H, KUTI D P. Nicolau. Prolonging beta-lactam infusion:a review of the rationale and evidence, and guidance for implementation[J]. Int J Antimicrob Agents, 2014,43(2):105-113.
[6]
EGUCHI K, KANAZAWA K, SHIMIZUDANI T, et al. Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation[J]. J Infect Chemother, 2010,16(1):1-9.
[7]
CHEN Y F, HANG Y F, XUE L, et al. Population pharmacokinetic study of biapenem in critical patients[J]. Chin Pharm J(�й�ҩѧ��־), 2016,51(6):478-482.
[8]
HOBAN D J, JONES R N, YAMANE N, et al. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide[J]. Diagn Microbiol Infect Dis, 1993,17(4):299-305.
[9]
WANG H,ZHANG B,NI Y, et al. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004[J]. Int J Antimicrob Agents, 2007,30(5):452-457.
[10]
PERRY C M. Ibbotson. Biapenem[J]. Drugs, 2002,62(15):2221-2234.
[11]
SHI J, HANG Y F, GAO J, et al. Optimization of therapeutic regimens of biapenem against Pseudomonas aeruginosa infection in elderly subjects in our hospital[J]. Chin Hosp Pharm J(�й�ҽԺҩѧ��־), 2017, 37(2):161-164.
[12]
HANG Y F, YU D, GAO J, et al. Monte carlo simulation improving therapeutic regimens of biapenem against enterobacteriaceae bacteria infection in elderly subjects[J]. Chin Pharm J(�й�ҩѧ��־), 2016, 51(12):1028-1032.
[13]
CHANT C A, LEUNG J O. Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions:a systematic review and meta-analysis[J]. Crit Care, 2013,17(6):R279.
[14]
Committee of Experts on Rational Drug Use, National Health and Family Planning Commission of the P.R.China, China Antimicrobial Resistance Surveillance System. China Antimicrobial Resistance Surveillance System Report 2015 [J]. China Lice Pharm(�й�ִҵҩʦ), 2016, 13(3):3-8.
[15]
DONG J, XIONG W, CHEN Y, et al. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation[J]. Int J Antimicrob Agents, 2016,47(3):202-209.
[16]
LIU J, XU J G, LU Q. Monte carlo simulation in optimization of Acinetbacter baumanni regimen [J]. Chin Hosp Pharm J(�й�ҽԺҩѧ��־), 2013, 33(6):460-463.
2017, Vol. 52 
